Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

BRAF binds KRAS, PIK3CA, and moaB. 1 / 1

| 1

➶

sparser

"Recently, changes in these pathways were also linked to anti-EGFR MoAb resistance. xref It was reported that mutations in KRAS, BRAF, and PIK3CA were associated with anti-EGFR MoAb resistance, and testing for these mutations was a potentially cost-effective way to improve survival in mCRC patients. xref , xref Of note, the mammalian target of rapamycin (mTOR) has been shown to be overactive in a series of human cancers and is emerging as potential target for drug development."

26586952

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...